$2.41
3.60% today
Nasdaq, Apr 03, 06:37 pm CET
ISIN
US8106481059
Symbol
SCPH
Sector
Industry

scPharmaceuticals, Inc. Stock price

$2.50
-0.71 22.12% 1M
-1.86 42.66% 6M
-1.04 29.38% YTD
-2.28 47.70% 1Y
-3.93 61.12% 3Y
-5.19 67.49% 5Y
-11.60 82.27% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.17 7.30%
ISIN
US8106481059
Symbol
SCPH
Sector
Industry

Key metrics

Market capitalization $125.71m
Enterprise Value $102.74m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.83
P/S ratio (TTM) P/S ratio 3.46
P/B ratio (TTM) P/B ratio 9.40
Revenue growth (TTM) Revenue growth 167.28%
Revenue (TTM) Revenue $36.33m
EBIT (operating result TTM) EBIT $-64.78m
Free Cash Flow (TTM) Free Cash Flow $-70.56m
Cash position $75.66m
EPS (TTM) EPS $-1.91
P/E forward negative
P/S forward 1.65
EV/Sales forward 1.35
Short interest 12.78%
Show more

Is scPharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

scPharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a scPharmaceuticals, Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a scPharmaceuticals, Inc. forecast:

Buy
100%

Financial data from scPharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
36 36
167% 167%
100%
- Direct Costs 11 11
167% 167%
32%
25 25
167% 167%
68%
- Selling and Administrative Expenses 77 77
48% 48%
213%
- Research and Development Expense 12 12
2% 2%
33%
-65 -65
18% 18%
-178%
- Depreciation and Amortization 0.17 0.17
73% 73%
0%
EBIT (Operating Income) EBIT -65 -65
17% 17%
-178%
Net Profit -85 -85
55% 55%
-234%

In millions USD.

Don't miss a Thing! We will send you all news about scPharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

scPharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
15 days ago
scPharmaceuticals Inc. (NASDAQ:SCPH ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Nick Colangelo - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President of Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen Glen Santangelo - Jefferies Roanna Ruiz - Leerink Partners Dougla...
Neutral
GlobeNewsWire
15 days ago
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX ® revenue of $12.2 million, and full year 2024 revenue of $36.3 million
Neutral
GlobeNewsWire
22 days ago
Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET
More scPharmaceuticals, Inc. News

Company Profile

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.

Head office United States
CEO John Tucker
Employees 164
Founded 2013
Website www.scpharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today